ClinicalTrials.gg

Program

equecabtagene autoleucel

Also written as “Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)”, “Equecabtagene Autoleucel Injection” and “Equecabtagene Autoleucel Injection (Eque-cel)”.

Its studies are mostly in Multiple Myeloma · Muscular Diseases, led by Nanjing IASO Biotechnology.

Furthest: phase 3, since May 30, 20245 company-led studies, 4 open or runningNext primary completion: Aug 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Nanjing IASO Biotechnology54 open or runningphase 3since May 30, 2024Sep 22, 2021Aug 2027phase 3 · NCT06464991

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 22, 2021First study: phase 2 study in Multiple MyelomaFirst studyNCT05066646 · 132 enrolled · China
  2. Nov 21, 2021Phase 1 study in Multiple MyelomaNCT05181501 · 20 planned · China
  3. Dec 29, 2022Phase 1 study in Multiple MyelomaNCT05698303 · 12 planned · United States
  4. May 30, 2024Phase 3 study in Multiple MyelomaNCT06464991 · 260 enrolled · China, Japan
  5. Aug 3, 2026Phase 2 study in Refractory Immune-mediated Necrotizing MyopathyNCT07752264 · 27 planned · China

Ahead

  1. Aug 2027Primary completion: phase 3 study in Multiple MyelomaNCT06464991
  2. Aug 15, 2030Primary completion: phase 2 study in Refractory Immune-mediated Necrotizing MyopathyNCT07752264

TargetBeta

TNFRSF17 →read by rule
“A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) with a fully human single chain variable fragment (scFv) targeting the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor”NCIt, by rule

Other programs on TNFRSF17

ProgramCompanyFurthest phaseStudies
elranatamabrulePfizerphase 415
linvoseltamabruleRegeneron Pharmaceuticalsphase 413
teclistamabruleJohnson & Johnsonphase 411
belantamab mafodotinruleGlaxoSmithKlinephase 325
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 312
etentamigAbbViephase 311
ramantamigJohnson & Johnsonphase 37
anitocabtagene autoleucelruleGilead Sciencesphase 36
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 34
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34
Evarucabgene Autoleucelrulenexcella-incphase 32
Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytesrulecartesian-therapeuticsphase 26

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07752264Refractory Immune-mediated Necrotizing Myopathy · China2Not yet recruitingAug 15, 203027
NCT06464991Multiple Myeloma · China, Japan3Active, not recruitingAug 2027260
NCT05698303Multiple Myeloma · United States1Not yet recruitingMay 20, 202412
NCT05181501Multiple Myeloma · China1Not yet recruitingApr 202420
NCT05066646Multiple Myeloma · China2UNKNOWNOct 2022132

How it is read

Names in the registry

  • “Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)”, 2 entries
  • “Equecabtagene Autoleucel Injection”, 1 entry
  • “Equecabtagene Autoleucel Injection (Eque-cel)”, 1 entry
  • “CT103A”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.